AstraZeneca to open new $300 million manufacturing facility in Maryland

Feb. 7, 2024
The plant will focus on the manufacturing of CAR-T cell therapies to enable cancer clinical trials.

AstraZeneca has announced plans to open a new manufacturing facility in Rockville, Maryland. The biopharmaceutical company will invest $300 million into the project, generating 150 new jobs in the process. Operations at the new 84,000 square-foot facility are expected to begin in 2026. According to the company, the plant will focus on the manufacturing of CAR-T cell therapies to enable cancer clinical trials. The Maryland Department of Commerce is in the process of approving a $500,000 conditional loan through the Advantage Maryland program, while Montgomery County’s Economic Development Fund will contribute an additional $100,000 conditional grant.

About the Author

Alexis Gajewski | Senior Content Strategist

Alexis Gajewski has over 15 years of experience in the maintenance, reliability, operations, and manufacturing space. She joined Plant Services in 2008 and works to bring readers the news, insight, and information they need to make the right decisions for their plants. Alexis also authors “The Lighter Side of Manufacturing,” a blog that highlights the fun and innovative advances in the industrial sector.